New Agent Misses the Mark in Advanced Prostate CancerNew Agent Misses the Mark in Advanced Prostate Cancer

The investigational agent orteronel failed to improve overall survival, but it did improve progression-free survival in men with castration-resistant prostate cancer. Medscape Medical News
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news